was linked to national mortality data.
prognostic information not provided by the TNM classification. 6 To date, there have been very few reports on the quantitative assessment of presenting symptoms and subsequent survival in head and neck cancer. 7 The Scottish Audit of Head and Neck Cancer (SAHNC) in 1999-2001 recorded the presenting symptoms of the patients recruited and provides an opportunity to assess the long-term survival profile of patients' symptoms with respect to subsite.
The aim of this study was to assess how the type and number of symptoms are related to survival in a large cohort of patients with head and neck cancer and discuss potential factors.
| MATERIALS AND METHODS

| Patients and data linkage
The SAHNC recruited 1895 patients between 1 September 1999 and 31 August 2001. Methods have previously been described. [8] [9] [10] [11] Data were recorded on all new patients with HNC diagnosed in Scotland. Quality assurance processes were carried out including cross-checking the incident data with medical and pathology results.
This article assesses a subset of 1589 patients, with the index cancer arising from one of the four main subsites; larynx, oropharynx, oral cavity and hypopharynx. The cohort was linked to the National Records of Scotland mortality data as at 30 September 2013 by ISD Scotland. Records were linked using the Howard Newcombe principle. 12 Information governance and data linkage approvals were obtained from the NHS Privacy Advisory Committee (now known as the Public Benefits and Privacy Panel).
| Determinants included in analysis
Determinants included age, sex, smoking behaviour, alcohol consumption, patient performance status, site, Stage, symptoms at presentation and treatment modality.
Symptoms were recorded at the time of diagnosis by the treating clinician, with key symptoms being recorded in numerical order, with the patient's principal symptom recorded first. This was in an "open structure basis" with the clinician being able to record up to three symptoms they considered of relevance. Each different symptom was given a numerical code for entry into the database. There were therefore no suggestions of symptoms to be recorded or pre-determined checklist for the treating clinician to use.
Stage was determined using the Tumour, Node and Metastases (TNM) Classification of Malignant Tumours, 13 and the cohort was grouped accordingly into Stage I/II/III/IV. Anatomical site was classified using the International Classification of Disease version 10, 14 and the cohort was grouped into 4 categories: larynx (C32), oral cavity (C02-C04, C05.0, C06, C14), oropharynx (C01, C05.1-, C09, C10) and hypopharynx (C12, C13).
Treatment modality was grouped into five categories: (i) surgery only; (ii) radiotherapy only; (iii) surgery combined with radiotherapy;
(iv) chemotherapy only, chemotherapy combined with surgery, chemotherapy combined with radiotherapy and chemotherapy combined with both surgery and radiotherapy; and (v) no treatment.
| Measurement of symptom
First, second and third presenting symptoms were recorded at diagnosis and included hoarseness, pain/discomfort, lump in neck, dysphagia, ulceration, weight loss, swelling, other/unknown. Variables for the number of symptoms each patient had were created, and additional binary "yes/no" variables for each presenting symptom were created. An interaction test confirmed a relationship between symptom and anatomical site, and therefore, the analysis was performed for all patients and each anatomical site (larynx, oral cavity, oropharynx and hypopharynx). If the resultant group was small, for example hoarseness in oral cancer subgroup, they were placed in "other/unknown" category.
| Statistical analysis
Five-year and 12-year disease-specific survival were calculated using the Kaplan-Meier method with 95% confidence intervals (CIs), and the log-rank test was used to determine the differences between the survival curves. Age-and Stage-adjusted Cox proportional hazard models were used to determine the differences in survival with 95% CIs.
3 | RESULTS
| Patient demographics
The study cohort of 1589 included larynx, oral cavity, oropharynx or hypopharynx cancer with all other subsites within the head and neck being excluded. The cohort consisted of 1146 (72%) males and 443 (28%) females. The mean age was 64 years (13-95 years). Table 1 shows the patient demographics for the study cohort. Larynx cancer was the most common subsite with 603 patients (38%), followed by oral cavity with 534 patients (34%), oropharynx with 330 patients (21%), then hypopharynx with 122 patients (7%). 
Keypoints
• Patient symptoms can give useful prognostic information.
• Patient presenting symptoms should be considered when discussing treatment planning.
• Patient symptoms can be used in discussions with patients.. with hoarseness had a significantly (P < .001) better survival than those who did not have hoarseness at both 5 and 12 years, with the median survival of a patient presenting with hoarseness being 5.9 years compared to 2.6 years for a patient without hoarseness.
| Survival
Patients presenting with a neck lump only had a median survival of Patients who had weight loss as a presenting symptom had a median survival of 1.3 years, which after adjustment for age and Stage in multivariate analysis was still a significant factor (P = .003). Patients who presented with a neck lump had a median survival of 1.8 years compared to 2.6 years for those without a neck lump. Table 5 demonstrates the median survival of patients diagnosed with hypopharyngeal cancer. There was no significant difference in median survival by the number of symptoms they presented with: patients with 1 symptom had the same median survival as patients who presented with 3 symptoms-1.1 years. However, it should be noted that the numbers of hypopharynx patients were much smaller than the other subsites.
| Symptoms
| Larynx cancer patients
| Oral cavity cancer patients
| Hypopharynx cancer patients
3.4 | Age-and stage-adjusted analyses 
| Symptoms as a predictor of prognosis
Cancer symptoms (type, duration, severity) and the performance status of the patient are clinical elements that represent the severity of the cancer in the patient. Using symptoms as a predictor of prognosis is not a new idea to head and neck cancer; however to date, symptoms have failed to make it into any formal staging system or help direct treatment and predict prognosis. Over 50 years ago, Jackson and Norris discussed the prognostic significance of "increasing degrees of dyspnoea, stridor, hoarseness and dysphagia, with persistent pain on swallowing and progressive cachexia" in a review article about laryngeal cancer. 15 | 801 disease, no matter how many symptoms they present with. However, it should be noted that we did have small numbers of hypopharyngeal cancer compared to the other subsites.
Our results also highlight that patients with specific symptoms, and confirmed head and neck cancer at a specific subsite, have an added indicator of prognosis. In our cohort, patients who presented with hoarseness, and diagnosed with larynx cancer specifically, had a median survival of 7 years, demonstrating the "good" prognosis associated with hoarseness. In stark contrast, weight loss was a significant predictor of poor prognosis in all four subsites in this series, even after adjustment for age and stage. The median survival for a patient with weight loss was only 0.8 year, and the worst median survival for all the symptoms was examined. Weight loss has previously been shown to be an independent prognostic factor in palliative care patients. 16 The significance of weight loss has been reported previously in patients with recurrent oral cavity and oropharyngeal cancer; 17 however, this is the first study in head and neck cancer to highlight its significance in median survival. At present, the MDT decision-making process focuses on the TNM staging of the primary tumour. However, there is now increasing evidence that specific types and number of symptoms are of prognostic value.
There is an argument for using this information not only in the decision-making process in treatment planning but also in informed discussions with patients. To develop this concept, a more rigorous approach of symptom recording, using an agreed symptom group, reflecting prognosis, could be implemented and recorded and the relationship with outcome noted.
| Value of red flag symptoms
One of the difficulties with red flag symptoms in head and neck cancer is that there are symptoms which are frequently experienced by T A B L E 6 Age-and stage-adjusted hazard ratios for disease-specific survival icant association of dysphagia with head and neck cancer, and this study adds further evidence to the need for this symptom to be included as a "red flag" needing a USOC referral. 22 The presence of pain in the form of sore throat or otalgia was present as a "red flag" symptom in the 2005 NICE guidelines, but was removed in the updated 2015 version. Pain as a symptom at diagnosis in this series was associated with a 2.3-year median survival, compared to 4.8-year median survival for those without pain. This significant difference in median survival would suggest that pain should be reintroduced to the "red flag" symptoms requiring urgent referral, a finding also highlighted by Tikka et al. 22 Weight loss is a very common symptom in patients with cancer and is not specific to head and neck cancer. However, this study highlights the poor prognostic significance of weight loss as a presenting symptom. Weight loss was an independent prognostic factor for survival at all four subsites after adjustment for age and stage. Weight loss has not been a "red flag" symptom for head and neck cancer in the NICE guidelines of 2005 or 2015, but it may be that unexplained weight loss should be considered for inclusion in future "red flag" symptoms.
The second issue is to refine the chosen head and neck red flag symptoms to yield a higher proportion of head and neck cancer. Currently, patients who present with persistent unexplained hoarseness for over 3 weeks need a 2-week referral for urgent suspicious of cancer (USOC). Our study highlights that a patient who presents with hoarseness, and is subsequently diagnosed with a squamous cell carcinoma of the head and neck, has a median survival of 5.9 years; if they are subsequently diagnosed with laryngeal squamous cell carcinoma the median survival is 7 years, arguably a very good prognosis. Given this prognosis, it could be suggested that the referral USOC for hoarseness should be voice "never normal" for over 6 weeks, excluding most of the "non-structural" dysphonic patients from the USOC clinics.
The "evidence" for the "red flags" in laryngeal and oral cancer was based on one publication, 23 highlighting a significant failing in the development of these guidelines. However, it may be that there simply is not the evidence base at present to develop true "evidence-based" guidelines, and this is an area that requires further research.
| Strengths and limitations of the study
The main limitation of this study was the accuracy of the recording of the symptoms. As this was designed to simply describe the study cohort at diagnosis, multiple clinicians were involved, and symptom recording was as reported by the patient, not based on an interrogation using a pre-determined agreed list of symptoms. Although this potential inaccuracy could be used as an argument for not using symptoms as a prognostic tool, compared to an "objective" TNM Stage, this could be addressed using an agreed symptom checklist. This is supported by Picirrillo who demonstrated, in a series of patients with larynx cancer, that symptom staging was just as reliable as the anatomical staging. 6 A strength of this study is the large number of patients which were included in the original head and neck audit, and furthermore the long-term survival data which we have in relation to the patients. Furthermore, the applicability of the findings are twofold;
firstly, it could be used to help direct symptom presentation for the early detection of head and neck cancer, and secondly, it could be used to help build prognostic models and treatment planning discussions with the patient.
| CONCLUSION
This study highlights the value of using patients' symptoms throughout a patient's journey, from when they first present in primary care
with "red flag" symptoms to direct urgent referrals, and in specialist cancer units to support the diagnosis, treatment planning, prognosis and communication with patients. As many symptoms appear to be of prognostic value, there is a need for more "symptom research"
prior to the updating of national guidelines and involvement in staging systems. 
